H.C. Wainwright analyst Brandon Folkes raised the firm’s price target on Milestone Pharmaceuticals (MIST) to $8 from $5 and keeps a Buy rating on the shares following the approval of Cardamyst for the treatment of paroxysmal supraventricular tachycardia. The shares at curet levels underappreciate the commercial opportunity of Cardamyst in PSVT, the analyst tells investors in a research note. H.C. Wainwright expects commercial outperformance and the re-initiation of the AFib-RVR trial to drive share momentum over the next 12 to 18 months.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIST:
- Milestone Pharmaceuticals Gains FDA Approval for CARDAMYST
- Milestone Pharmaceuticals receives FDA approval of CARDAMYST
- Milestone Pharmaceuticals trading halted, news pending
- Milestone Pharmaceuticals: Buy Rating Reaffirmed Amid Imminent PDUFA Date and Misunderstood CRL Implications
- Milestone Pharmaceuticals Reports Q3 2025 Financial Results